QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system 期刊论文 DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 卷号: 13 作者:  An, Qing;  Zheng, Yingxin;  Zhao, Yirong;  Liu, Tao;  Guo, Huaizu 收藏  |  浏览/下载：15/0  |  提交时间：2019/12/05 infliximab  biosimilar  "biobetter"  CMAB008  immunogenicity   In-Depth Characterization of a Pro-Antibody-Drug Conjugate by LC-MS 期刊论文 MOLECULAR PHARMACEUTICS, 2016, 卷号: 13, 期号: 8 作者:  Liu, Boning;  Guo, Huaizu;  Zhang, Junjie;  Xue, Jingya;  Yang, Yun 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 pro-antibody-drug conjugates  structural characterization  drug-to-antibody ratio  drug load distribution  drug-loaded peptide mapping  drug occupation site  IdeS  liquid chromatography mass spectrometry  charge heterogeneity   Development and Validation of a Peptide Mapping Method for the Characterization of Adalimumab with QDa Detector 期刊论文 CHROMATOGRAPHIA, 2016, 卷号: 79, 页码: 395-403 作者:  Zhang, Junjie[1,2,3];  Qin, Ting[1,2,3];  Xu, Lu[1,2,3];  Liu, Boning[1,2,3];  Li, Yantao[2,3] 收藏  |  浏览/下载：6/0  |  提交时间：2019/04/24 LC-QDa  Adalimumab  CDR regions  Peptide mapping   Molecular architecture of the ErbB2 extracellular domain homodimer 期刊论文 Oncotarget, 2015, 卷号: 6, 期号: 3 作者:  Hu, Shi/56434897100[0];  Sun, Yuna/8845600300[1];  Meng, Yanchun/36994996100[2];  Wang, Xiaoze/55863421400[3];  Yang, Weili/55501159500[4] 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/13 Crystal structure  Dimerization  ErbB2  Oncogene  Signal transduction   Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View 期刊论文 Journal of Biological Chemistry, 2013, 卷号: Vol.288 No.38, 页码: 27059-27067 作者:  Shi Hu;  Shuaiyi Liang;  Huaizu Guo;  Dapeng Zhang;  Hui Li 收藏  |  浏览/下载：5/0  |  提交时间：2019/02/27 Antibodies  Autoimmune Diseases  Crystal Structure  Protein Targeting  Tumor Necrosis Factor (TNF)  Adalimumab  Epitope  Mechanism